Abstract:Immunotherapy strategies have been emerging as powerful weapons against cancer. Early clinical trials reveal that overall response to immunotherapy is low in breast cancer patients, suggesting that effective strategies to overcome resistance to immunotherapy are urgently needed. In this study, we investigated whether epigenetic reprograming by modulating histone methylation could enhance effector T lymphocyte trafficking and improve therapeutic efficacy of immune checkpoint blockade in breast cancer with focus on triple-negative breast cancer (TNBC) subtype. In silico analysis of The Cancer Genome Atlas (TCGA) data shows that expression of histone lysine-specific demethylase 1 (LSD1) is inversely associated with the levels of cytotoxic T cell-attracting chemokines (C-C motif chemokine ligand 5 (CCL5), C-X-C motif chemokine ligand 9 and 10 (CXCL9, CXCL10)) and programmed death-ligand 1 (PD-L1) in clinical TNBC specimens. Tiling chromatin immunoprecipitation study showed that re-expression of chemokines by LSD1 inhibition is associated with increased H3K4me2 levels at proximal promoter regions. Rescue experiments using concurrent treatment with small interfering RNA or inhibitor of chemokine receptors blocked LSD1 inhibitor-enhanced CD8+ T cell migration, indicating a critical role of key T cell chemokines in LSD1-mediated CD8+ lymphocyte trafficking to the tumor microenvironment. In mice bearing TNBC xenograft tumors, anti-PD-1 antibody alone failed to elicit obvious therapeutic effect. However, combining LSD1 inhibitors with PD-1 antibody significantly suppressed tumor growth and pulmonary metastasis, which was associated with reduced Ki-67 level and augmented CD8+ T cell infiltration in xenograft tumors. Overall, these results suggest that LSD1 inhibition may be an effective adjuvant treatment with immunotherapy as a novel management strategy for poorly immunogenic breast tumors.

Research progress of histone lysine-specific demethylase 1 in cancer immunoediting

Targeting LSD1 in cancer: Molecular elucidation and recent advances

LSD1: an Emerging Face in Altering the Tumor Microenvironment and Enhancing Immune Checkpoint Therapy

Overview and new insights of lysine-specific histone demethylase 1 in colorectal cancer: promoting epithelial-mesenchymal transition and stemness features of cancer stem cells

Lysine methylation modifications in tumor immunomodulation and immunotherapy: regulatory mechanisms and perspectives

The role of histone methylase and demethylase in antitumor immunity: A new direction for immunotherapy

Novel Insights into Histone Lysine Methyltransferases in Cancer Therapy: from Epigenetic Regulation to Selective Drugs

The Progress in Exploring the Structure and Function of Histone Demethylase LSD1

Therapeutic potential of targeting LSD1/ KDM1A in cancers

Histone Demethylase Lysine Demethylase 5B in Development and Cancer

Lysine-specific Histone Demethylase 1 (LSD1): A Potential Molecular Target for Tumor Therapy

Inhibition of histone lysine-specific demethylase 1 elicits breast tumor immunity and enhances antitumor efficacy of immune checkpoint blockade

H3K4 trimethylation regulates cancer immunity: a promising therapeutic target in combination with immunotherapy

Tumor Immune Checkpoints and Their Associated Inhibitors

Epigenetic regulation of cancer progression by EZH2: from biological insights to therapeutic potential

The Roles of H3K9me3 Writers, Readers, and Erasers in Cancer Immunotherapy

The function of histone methyltransferase SETDB1 and its roles in liver cancer

LSD1 is a promising target to treat cancers by modulating cell stemness

Epigenetic regulation in the tumor microenvironment: molecular mechanisms and therapeutic targets

The role of histone post-translational modifications in cancer and cancer immunity: functions, mechanisms and therapeutic implications

Role of histone methyltransferase SETDB1 in regulation of tumourigenesis and immune response.